Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FHCC8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,386
Award facts
- Contract value 100% obligated
- $10,386.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,386 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of BOTOX 200 Unit Vials. The contract, issued on January 26, 2026, with an ultimate completion date of February 17, 2026, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to consolidate pharmaceutical sourcing for Department of Defense medical facilities worldwide.
As a prime vendor under PPV-G GEN V, DMS Pharmaceutical Group has been authorized to supply a comprehensive range of pharmaceuticals and medical consumables to support recurring medical supply needs across military healthcare operations. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with a performance period extending through December 31, 2036, enabling the Defense Logistics Agency to issue firm fixed-price delivery orders for specialized pharmaceutical products. DMS Pharmaceutical Group's established performance across numerous prior delivery orders and its extensive product portfolio, which includes oncology treatments, biologics, vaccines, and specialty pharmaceuticals, demonstrate the company's capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHCC8?
SPE2DR26FHCC8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FHCC8 worth?
The government has obligated $10,386 on SPE2DR26FHCC8.
Is contract SPE2DR26FHCC8 an order under another contract?
Yes. SPE2DR26FHCC8 is a delivery order under SPE2DR25D9205, an indefinite delivery contract.
Was contract SPE2DR26FHCC8 competed?
The extent of competition for SPE2DR26FHCC8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award